Recently， microtubule-binding proteins (MBPs) have been implicated in modulation of paclitaxel sensitivity in many cancers， highlighting their potential as biomarkers predictive of treatment outcomes and as therapeutic targets that can be pharmacologically manipulated. This study is aimed to determine the impact of the MBP hematopoietic PBX-interaction protein (HPIP) on breast cancer cell sensitivity to paclitaxel.
Recently， microtubule-binding proteins (MBPs) have been implicated in modulation of paclitaxel sensitivity in many cancers， highlighting their potential as biomarkers predictive of treatment outcomes and as therapeutic targets that can be pharmacologically manipulated. This study is aimed to determine the impact of the MBP hematopoietic PBX-interaction protein (HPIP) on breast cancer cell sensitivity to paclitaxel.
